Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Fulcrum Therapeutics (NASDAQ:FULC) from a "sell" to a "strong sell" in a research report released Sunday.
• MarketBeat's consensus remains a Moderate Buy with an average price target of $19, reflecting a split among analysts (seven Buys, one Hold, two Sells).
• Shares trade around $7.55 (1‑year range $2.54–$15.74) with negative EPS and a market cap near $503M, and institutions own about 89.8% after several funds markedly increased their stakes.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued to clients and investors on Sunday.

A number of other equities research analysts also recently commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Truist Financial set a $17.00 target price on Fulcrum Therapeutics in a research report on Tuesday, February 24th. JPMorgan Chase & Co. initiated coverage on Fulcrum Therapeutics in a research report on Monday, January 12th. They issued an "overweight" rating and a $20.00 target price on the stock. Finally, Leerink Partners restated an "outperform" rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $19.00.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC opened at $7.55 on Friday. Fulcrum Therapeutics has a 1 year low of $2.54 and a 1 year high of $15.74. The firm has a market capitalization of $502.83 million, a P/E ratio of -6.40 and a beta of 3.27. The business's 50-day moving average is $8.60 and its 200 day moving average is $9.64.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, meeting analysts' consensus estimates of ($0.31). On average, analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC grew its stake in Fulcrum Therapeutics by 21.9% during the 4th quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company's stock worth $74,206,000 after purchasing an additional 1,180,111 shares in the last quarter. Nantahala Capital Management LLC grew its stake in Fulcrum Therapeutics by 8.9% during the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company's stock worth $42,971,000 after purchasing an additional 382,485 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company's stock worth $31,572,000 after purchasing an additional 1,589,000 shares in the last quarter. Braidwell LP grew its stake in Fulcrum Therapeutics by 1,294.7% during the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company's stock worth $34,622,000 after purchasing an additional 2,841,734 shares in the last quarter. Finally, Siren L.L.C. acquired a new position in Fulcrum Therapeutics during the 4th quarter worth $22,054,000. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.